Nicholas W. Fischer

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

Aaron Prodeus, Aws Abdul‐Wahid, Nicholas W. Fischer et al. · Molecular Therapy — Nucleic Acids · 2015 · 141 citations · Full text

Immunology, Immunoediting, Immunotherapy +17

p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis

Nicholas W. Fischer, Aaron Prodeus, David Malkin et al. · Cell Cycle · 2016 · 68 citations · Full text

Dimeric P53 Variants, Apoptosis, Cell Death +18

VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses

Aaron Prodeus, Aws Abdul‐Wahid, Amanda Sparkes et al. · JCI Insight · 2017 · 40 citations · Full text

Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome

Nicholas W. Fischer, Aaron Prodeus, James Tran et al. · JNCI Journal of the National Cancer Institute · 2018 · 28 citations · Full text

Li-fraumeni Syndrome, Oncology, Oligomeric Status +14

<scp>S</scp>erum‐derived carcinoembryonic antigen (<scp>CEA</scp>) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of <scp>CEA</scp>‐expressing tumor cells

Aws Abdul‐Wahid, Marzena Cydzik, Nicholas W. Fischer et al. · International Journal of Cancer · 2018 · 25 citations

Crc Patients, Pathology, Tumor Cells +18